Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Kate Kelley, Robin; Sangro, Bruno; Harris, William; Ikeda, Masafumi; Okusaka, Takuji; Kang, Yoon-Koo; Qin, Shukui; W.-M. Tai, David; Yeong Lim, Ho; Yau, Thomas; Yong, Wei-Peng; Cheng, Ann-Lii; Gasbarrini, Antonio; Damian, Silvia; Bruix, Jordi; Borad, Mitesh; Bendell, Johanna; Kim, Tae-You; Standifer, Nathan; He, Philip; Makowsky, Mallory; Negro, Alejandra; Kudo, Masatoshi; K. Abou-Alfa, Ghassan

doi:10.1200/jco.20.03555

Public

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Shared by NobleBlocks on Sep 20, 2021 • 12:00 AM UTC

Authors:

Robin Kate Kelley

Bruno Sangro

William Harris

Abstract

PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a...

Discussions